Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cholinergic Receptor Block Therapy for ALS
NCT04391361Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Nov 2020
- Primary completion
- Sep 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of scopolamine, atropine and dexmedetomidine in amyotrophic lateral sclerosis (ALS), sponsored by Ruijin Hospital. Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 48 weeks. Status: unknown.
02
Drugs
scopolamineatropinedexmedetomidine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04391361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391361.